clopidogrel has been researched along with Chronic Kidney Diseases in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.23) | 29.6817 |
| 2010's | 43 (69.35) | 24.3611 |
| 2020's | 17 (27.42) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H | 1 |
| De Luca, L; Ferraro, PM; Gabrielli, D; Grigioni, F; Mangiacapra, F; Mangiacapra, R; Melfi, R; Nusca, A; Paolucci, L; Ussia, GP; Viscusi, MM | 1 |
| Chen, J; Huang, XR; Lan, HY; Tang, PM; Tang, Y; Wei, B; Xu, A; Zhong, Y | 1 |
| DE Luca, G; Gioscia, R; Kedhi, E; Nardin, M; Rognoni, A; Suryapranata, H; Verdoia, M | 1 |
| Arthur, JM; Arulprakash, N; Corken, A; Dai, J; Davis, O; Hedayati, SS; Jain, N; Mehta, JL; Phadnis, MA; Rahmatallah, Y; Smyth, S; Ware, J | 1 |
| Ge, P; Guo, Y; Li, Z; Xiao, J; Xie, L | 1 |
| Anyanor, A; Eze, H; Jisieike-Onuigbo, NN; Kalu, AO; Ndulue, CN; Odenigbo, CU; Oguejiofor, F; Okwesa, NJ; Osakwe, N; Ozuemba, BC | 1 |
| Ballantyne, K; Barrett, JW; Bootland, D; Da Costa, A; Davies, R; Griggs, JE; Leung, J; Lyon, RM; Skene, SS; Williams, J | 1 |
| Akbari, A; Barry, JP; Gravenor, MB; Halcox, JP; Harris, DE; Jenkins, GH; Lacey, A; Obaid, DR; Smith, DA | 1 |
| Ali, ZA; Baber, U; Ben-Yehuda, O; Brodie, BR; Chen, S; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Redfors, B; Rinaldi, MJ; Rubin, GA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Zhang, Y | 1 |
| Angiolillo, DJ; Bergmeijer, TO; Capodanno, D; Danchin, N; Price, MJ; Sibbing, D; Simon, T; Ten Berg, JM | 1 |
| Cho, JH; Jeong, KH; Kim, HO; Kim, JM; Kim, JS; Kim, W; Lee, SR; Rhew, JH; Woo, JS | 1 |
| Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K | 1 |
| Bonello, L; Burtey, S; Canault, M; Cayla, G; Laine, M; Lemesle, G; Paganelli, F; Pankert, M; Puymirat, E; Quaino, G; Range, G | 1 |
| Cimino, S; Cirillo, P; Coscioni, E; Esposito, G; Ferrone, M; Gargiulo, G; Giugliano, G; Ilardi, F; Morisco, C; Paolillo, R; Perrino, C; Schiattarella, GG; Stabile, E; Verde, N | 1 |
| Abou Jaoude, P; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X | 1 |
| Bastos-Fernandez, G; Baz-Alonso, JA; Cruz-González, I; De Miguel-Castro, A; Fernández-Barbeira, S; Figueiras-Guzman, A; Iñiguez-Romo, A; Jimenez-Diaz, VA; Molina-Navarro, E; Moreno, R; Ortiz-Saez, A; Paredes-Galán, E; Romaguera, R; Salvadores, PJ; Tello-Montoliu, A; Trejo-Velasco, B | 1 |
| Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S | 1 |
| Chen, WC; Chuah, SK; Hsu, PI; Huang, YT; Lin, KH; Sun, WC; Tsai, TJ; Wu, DC | 1 |
| Gurm, HS | 1 |
| Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Faggioni, M; Farhan, S; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J | 1 |
| Han, Y; Li, C; Li, J; Li, Y; Qi, J; Tang, Y; Wang, H | 1 |
| Bonello, L; Burtey, S; Laine, M; Lemesle, G; Puymirat, E | 1 |
| Lozano, I; Rondan, J; Segovia, E; Vegas, JM | 1 |
| Carrillo-Alemán, L; Esteve-Pastor, MA; Lozano, T; Macías-Villanego, MJ; Marín, F; Martínez-Martínez, JG; Orenes-Piñero, E; Pernias-Escrig, V; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Tello-Montoliu, A; Véliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Aradi, D; Bonello, L; Burtey, S; Dabry, T; Frere, C; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Puymirat, E; Sibbing, D; Thuny, F | 1 |
| Angiolillo, DJ; Budaj, AJ; Cornel, JH; Franchi, F; Ghukasyan Lakic, T; Himmelmann, A; James, SK; Katus, HA; Keltai, M; Kontny, F; Lewis, BS; Storey, RF; Wallentin, L | 1 |
| Deng, BQ; Feng, ZM; Ke, X; Lin, YQ; Nie, RQ; Shu, XR | 1 |
| Gong, Y; Pan, Y; Song, Y; Wu, Y; Zhou, Y | 1 |
| Fischer, MJ; Ho, PM; Lowy, E; McDermott, K; Parikh, CR | 1 |
| Araujo, KL; Argento, AC; Murphy, TE; Pisani, MA; Puchalski, JT | 1 |
| Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL | 1 |
| Hou, MC; Hu, HY; Lee, FY; Lin, CC; Lin, HC; Luo, JC; Peng, YL | 1 |
| Alexopoulos, D | 1 |
| Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Tanahashi, N | 1 |
| Barbato, E; Cavallari, I; D'Ambrosio, A; De Bruyne, B; Di Sciascio, G; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R | 1 |
| Bouatou, Y; Gabrielli, A; Saudan, P | 1 |
| Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y | 1 |
| Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Jung, JM; Kim, K; Kim, S; Koh, JS; Kwak, CH; Park, JR; Park, Y; Tantry, US | 1 |
| Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C | 1 |
| Cairns, JA; Connolly, S; Cox, JL; Dorian, P; Gladstone, D; Healey, JS; Ivers, N; Leblanc, K; Macle, L; McMurtry, MS; Mitchell, LB; Nattel, S; Stiell, IG; Verma, A | 1 |
| Chae, IH; Cho, YS; Choi, DJ; Kim, HS; Kim, SH; Lee, SA; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ | 1 |
| Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Siddiqi, OK; Smoot, KJ; Temiyasathit, S; Young, M | 1 |
| Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Hafley, G; Melloni, C; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Zamoryakhin, D | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Adams-Huet, B; Banerjee, S; Hedayati, SS; Jain, N; Li, X; Sarode, R; Toto, RD | 1 |
| Cavallari, LH; Mason, DL | 1 |
| Adamo, M; Ariotti, S; Costa, F; Crimi, G; Leonardi, S; Valgimigli, M | 1 |
| Caillard, S; Cognard, N; Gautier-Vargas, G; Messas, N; Morel, O; Moulin, B; Muller, C; Olagne, J; Perrin, P | 1 |
| Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y | 1 |
| Alobaidi, Z; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Engwenyu, LR; Ferrante, E; Franchi, F; Jakubowski, JA; Rollini, F; Sugidachi, A; Zenni, M | 1 |
| Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C | 1 |
| Al Suwaidi, J; El-Menyar, A; Hussein, H | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Moro, PJ; Pons, C; Quilici, J | 1 |
| Caillard, S; Campia, U; El Ghannudi, S; Gachet, C; Jesel, L; Meyer, N; Morel, O; Moulin, B; Ohlmann, P; Radulescu, B; Wiesel, ML | 1 |
| Arai, T; Fukuda, K; Ikeda, Y; Kawamura, A; Matsubara, Y; Murata, M; Yokoyama, K | 1 |
| Ahn, YK; Chae, IH; Chae, SC; Cho, MC; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, JY; Kim, YJ; Moon, JH; Park, SJ; Seong, IW; Seung, KB; Yoon, JH | 1 |
| Cao, J; Cong, YL; Cui, H; Fan, L; Hu, GL; Hu, QQ; Leng, WX; Niu, H; Ren, JW | 1 |
| Lepor, NE | 1 |
| Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ | 1 |
10 review(s) available for clopidogrel and Chronic Kidney Diseases
| Article | Year |
|---|---|
Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Thrombosis; Treatment Outcome | 2022 |
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Treatment Outcome | 2023 |
Head injury in older adults presenting to the ambulance service: who do we convey to the emergency department, and what clinical variables are associated with an intracranial bleed? A retrospective case-control study.
Topics: Aged; Ambulances; Case-Control Studies; Clopidogrel; Craniocerebral Trauma; Emergency Service, Hospital; Humans; Intracranial Hemorrhages; Middle Aged; Observational Studies as Topic; Renal Insufficiency, Chronic; Retrospective Studies | 2023 |
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; France; Hemorrhage; Humans; Odds Ratio; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Survival Analysis; Ticagrelor; Treatment Outcome | 2018 |
High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Risk Factors; Stents; Treatment Outcome | 2019 |
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Ticlopidine; Treatment Outcome | 2014 |
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Precision Medicine; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Solute Carrier Proteins; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin | 2016 |
Coronary stent thrombosis in patients with chronic renal insufficiency.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency, Chronic; Risk Factors; Stents; Ticlopidine | 2010 |
Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Drug-Eluting Stents; Glucose; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2006 |
16 trial(s) available for clopidogrel and Chronic Kidney Diseases
| Article | Year |
|---|---|
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease.
Topics: Adenosine; Clopidogrel; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Secondary Prevention; Thrombosis; Ticagrelor; Young Adult | 2020 |
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Renal Insufficiency, Chronic; Ticagrelor | 2022 |
Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation.
Topics: Aged; Aged, 80 and over; Anemia; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Spain; Ticagrelor; Time Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2021 |
Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Elimination; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Comorbidity; Diabetes Mellitus; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Survival Rate; Ticagrelor; United States | 2019 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Resistance; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.
Topics: Cardiovascular Diseases; Cilostazol; Clopidogrel; Female; Follow-Up Studies; Humans; Lansoprazole; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Prospective Studies; Proton Pump Inhibitors; Renal Insufficiency, Chronic; Stents; Tetrazoles; Ticlopidine | 2014 |
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Hepatic Insufficiency; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Renal Insufficiency, Chronic; Republic of Korea; Research Design; Serotonin Antagonists; Succinates; Ticlopidine | 2015 |
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Renal Insufficiency, Chronic; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODI
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Metals; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Renal Insufficiency, Chronic; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Comorbidity; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Ischemic Attack, Transient; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Severity of Illness Index; Stroke; Ticlopidine | 2016 |
Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Prognosis; Renal Insufficiency, Chronic; Republic of Korea; Retrospective Studies; Risk Factors; Stents; Survival Rate; Ticlopidine | 2012 |
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Stents; Ticlopidine; Treatment Outcome | 2008 |
36 other study(ies) available for clopidogrel and Chronic Kidney Diseases
| Article | Year |
|---|---|
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Drug Therapy, Combination; Female; Genotype; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Renal Insufficiency, Chronic; Stroke; Treatment Outcome | 2022 |
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.
Topics: Animals; Clopidogrel; Fibrosis; Kidney; Kidney Diseases; Macrophages; Mice; Mice, Inbred C57BL; Myofibroblasts; Renal Insufficiency, Chronic; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ureteral Obstruction | 2022 |
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2023 |
Clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; Renal Insufficiency, Chronic; Ticlopidine | 2023 |
Early Discontinuation of P2Y
Topics: Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Prescriptions; Female; Hemorrhage; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Retreatment; Retrospective Studies; Stroke; Thromboembolism; Wales | 2019 |
Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Germany; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Registries; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
Topics: Age Factors; Aged; Body Mass Index; Clinical Decision Rules; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Databases, Factual; Diabetes Mellitus; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Obesity; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Reproducibility of Results; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Platelet activity with hemoglobin level in patients with hemodialysis: Prospective study.
Topics: Aged; Clopidogrel; Female; Hemoglobins; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Stroke | 2020 |
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Treatment Outcome | 2020 |
Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Renal Insufficiency, Chronic; Ticlopidine | 2022 |
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Clopidogrel; Comorbidity; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dose-Response Relationship, Drug; Female; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Incidence; Male; Middle Aged; Peptic Ulcer; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Renal Insufficiency, Chronic; Risk Factors; Selective Serotonin Reuptake Inhibitors; Taiwan; Ticlopidine; Warfarin; Young Adult | 2017 |
P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Databases, Factual; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization Review; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2017 |
Research and Therapeutic Nihilisms in Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Kidney Failure, Chronic; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Renal Insufficiency, Chronic | 2017 |
Chronic Kidney Disease and Antiplatelet Therapy: A Worrying Gap Between Evidence Based Medicine and Clinical Practice.
Topics: Acute Coronary Syndrome; Clopidogrel; Evidence-Based Medicine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic | 2018 |
Chronic Kidney Disease and Third-Generation P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prognosis; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic | 2019 |
Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Flow Cytometry; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Stents; Time Factors | 2019 |
Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Hospitalization; Hospitals, Veterans; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Ticlopidine; Treatment Outcome | 2013 |
The safety of thoracentesis in patients with uncorrected bleeding risk.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Clopidogrel; Cohort Studies; Drainage; Female; Hepatic Insufficiency; Humans; International Normalized Ratio; Male; Middle Aged; Platelet Aggregation Inhibitors; Pleural Effusion; Postoperative Hemorrhage; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Thrombocytopenia; Ticlopidine; Warfarin | 2013 |
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Renal Insufficiency, Chronic; Taiwan; Ticlopidine; Treatment Outcome | 2013 |
Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Peptic Ulcer Hemorrhage; Platelet Aggregation Inhibitors; Proportional Hazards Models; Regression Analysis; Renal Insufficiency, Chronic; Risk Factors; Selective Serotonin Reuptake Inhibitors; Taiwan; Ticlopidine | 2013 |
Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Stroke; Ticlopidine; Treatment Outcome | 2014 |
Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Electrocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Prospective Studies; Renal Insufficiency, Chronic; Ticlopidine | 2014 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; Data Collection; Denmark; Female; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ticlopidine; Treatment Outcome | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clopidogrel; Comorbidity; Dabigatran; Electric Countershock; Humans; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine | 2014 |
Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metals; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2016 |
Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study.
Topics: Aged; Clopidogrel; Cohort Studies; Female; Humans; Kidney Transplantation; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Ticlopidine | 2016 |
Impact of chronic kidney disease on platelet P2Y
Topics: Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Resistance; Humans; Microfilament Proteins; Phosphoproteins; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Renal Insufficiency, Chronic; Signal Transduction; Ticlopidine | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticlopidine | 2010 |
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Cause of Death; Clopidogrel; Cohort Studies; Coronary Stenosis; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Reference Values; Renal Insufficiency, Chronic; Risk Assessment; Survival Analysis; Ticlopidine | 2011 |
Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Insufficiency, Chronic; Retrospective Studies; Ticlopidine | 2012 |
Chronic kidney disease--is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?
Topics: Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatinine; Female; Hemoglobins; Humans; Male; Odds Ratio; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Regression Analysis; Renal Insufficiency, Chronic; Risk Factors; Ticlopidine; Treatment Outcome | 2013 |